ELI LILLY: PARTICIPANTS TAKING ELORATZP LOWERED THEIR A1C BY UP TO AVERAGE OF 2.9% VS. 2.4% WITH TIRZEPATIDE 15 MG || AT 48 WEEKS, ALL COMBINATIONS OF ELORATZP MET PRIMARY & SECONDARY ENDPOINTS || PARTICIPANTS TAKING ELORATZP LOST UP TO AVERAGE OF 54.1 LBS (23.3%) VS. 34.4 LBS (14.8%) WITH TIRZEPATIDE 15 MG ...